Skip to main content

Advertisement

SpringerLink
Log in

Drug-induced parkinsonism

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Drug-induced parkinsonism (DIP) is condition that mimics Parkinson’s disease. Characterized mainly by rigidity and bradykinesia, it has less prominent tremor and gait instability. DIP is generally caused by lipophilic drugs that “block” dopamine D2 receptors in the brain, although presynaptic dopamine depletion, false transmitters, mitochondrial respiratory chain dysfunction, and overactivity in the γ-aminobutyric acid (GABA)ergic system or cholinomimetic action have also been postulated as possible mechanisms. The onset of DIP is acute to subacute. It is more common in women and has a bimodal age distribution. Other diseases that can resemble DIP include neuropsychiatric conditions (eg, depression, negative symptoms of schizophrenia) and Wilson’s disease.

Physicians may be able to prevent DIP by prescribing neuroleptic agents appropriately and with caution. The risk of DIP is presumably lower with the use of “atypical” antipsychotic agents but it is not eliminated, especially in those most vulnerable to parkinsonism (eg, the elderly or cognitively impaired). The best treatment is discontinuation of the provoking medication. Prospective studies are needed to further define the mechanism of DIP, identify individual susceptibility, determine the impact of atypical antipsychotic agents, and develop further treatment options for those unable to stop the offending agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Halliday J, Farrington S, Macdonald S, et al.: Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002, 181:422–427.

    Article  PubMed  Google Scholar 

  2. Ayd FJ Jr: A survey of drug-induced extrapyramidal reactions. JAMA 1961, 175:1054–1060.

    PubMed  CAS  Google Scholar 

  3. Ebadi M, Srinivasan SK: Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 1995, 47:575–604.

    PubMed  CAS  Google Scholar 

  4. Steck H: [Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments.] [article in French]. Ann Med Psychol (Paris) 1954, 112:737–744.

    CAS  Google Scholar 

  5. Ganzini L, Heintz R, Hoffman WF, et al.: Acute extrapyramidal syndromes in neuroleptic-treated elders: a pilot study. J Geriatr Psychiatry Neurol 1991, 4:222–225.

    Article  PubMed  CAS  Google Scholar 

  6. Modestin J, Stephan PL, Erni T, Umari T: Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000, 42:223–230.

    Article  PubMed  CAS  Google Scholar 

  7. Hobson P, Gallacher J, Meara J: Cross-sectional survey of Parkinson’s disease and parkinsonism in a rural area of the United Kingdom. Mov Disord 2005, 20:995–998.

    Article  PubMed  Google Scholar 

  8. de Rijk MC, Tzourio C, Breteler MM, et al.: Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997, 62:10–15.

    Article  PubMed  Google Scholar 

  9. Esper CD, Factor SA: Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008, 23:401–404.

    Article  PubMed  Google Scholar 

  10. McGeer PL, McGeer EG, Hattori T: Dopamine-acetylcholine-GABA neuronal linkages in the extrapyramidal and limbic systems. Adv Biochem Psychopharmacol 1977, 16:397–402.

    PubMed  CAS  Google Scholar 

  11. Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983, 40:1113–1117.

    PubMed  CAS  Google Scholar 

  12. Moleman P, Janzen G, von Bargen BA, et al.: Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. Am J Psychiatry 1986, 143:232–234.

    PubMed  CAS  Google Scholar 

  13. Montastruc JL, Llau ME, Rascol O, Senard JM: Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994, 8:293–306.

    PubMed  CAS  Google Scholar 

  14. Gordon JH, Gorski RA, Borison RL, Diamond BI: Postsynaptic efficacy of dopamine: possible suppression by estrogen. Pharmacol Biochem Behav 1980, 12:515–518.

    Article  PubMed  CAS  Google Scholar 

  15. Quinn N: Parkinsonism—recognition and differential diagnosis. BMJ 1995, 310:447–452.

    PubMed  CAS  Google Scholar 

  16. Hardie RJ, Lees AJ: Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988, 51:850–854.

    Article  PubMed  CAS  Google Scholar 

  17. Goetz CG: Drug-induced Parkinsonism and idiopathic Parkinson’s disease. Arch Neurol 1983, 40:325–326.

    PubMed  CAS  Google Scholar 

  18. Alvarez MV, Evidente VG: Understanding drug-induced parkinsonism: separating pearls from oy-sters. Neurology 2008, 70:e32–e34.

    Article  PubMed  Google Scholar 

  19. Hassin-Baer S, Sirota P, Korczyn AD, et al.: Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 2001, 108:1299–1308.

    Article  PubMed  CAS  Google Scholar 

  20. Booij J, Speelman JD, Horstink MW, Wolters EC: The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001, 28:266–272.

    Article  PubMed  CAS  Google Scholar 

  21. Merle U, Schaefer M, Ferenci P, Stremmel W: Clinical presentation, diagnosis and long-term outcome of Wilson’s disease: a cohort study. Gut 2007, 56:115–120.

    Article  PubMed  CAS  Google Scholar 

  22. Rajput AH, Uitti RJ, Stern W, et al.: Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson’s disease. Can J Neurol Sci 1987, 14(3 Suppl):414–418.

    PubMed  CAS  Google Scholar 

  23. Wilson JA, MacLennan WJ: Review: drug-induced parkinsonism in elderly patients. Age Ageing 1989, 18:208–210.

    Article  PubMed  CAS  Google Scholar 

  24. Nyberg S, Olsson H, Nilsson U, Maehlum E, et al.: Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 2002, 162:37–41.

    Article  CAS  Google Scholar 

  25. Nordstrom AL, Farde L, Halldin C: Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992, 106:433–438.

    Article  CAS  Google Scholar 

  26. Lieberman JA, Tollefson G, Tohen M, et al.: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003, 160:1396–1404.

    Article  PubMed  Google Scholar 

  27. Kapur S, McClelland RA, VanderSpek SC, et al.: Increasing D2 affinity results in the loss of clozapine’s atypical antipsychotic action. Neuroreport 2002, 13:831–835.

    Article  PubMed  CAS  Google Scholar 

  28. Tarsy D, Baldessarini RJ, Tarazi FI: Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002, 16:23–45.

    Article  PubMed  CAS  Google Scholar 

  29. Casey DE: Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004, 65(Suppl 9):25–28.

    PubMed  CAS  Google Scholar 

  30. Stahl SM: “Hit-and-run” actions at dopamine receptors, part 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics. J Clin Psychiatry 2001, 62:747–748.

    PubMed  CAS  Google Scholar 

  31. Arnt J, Skarsfeldt T: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18:63–101.

    Article  PubMed  CAS  Google Scholar 

  32. Rochon PA, Stukel TA, Sykora K, et al.: Atypical antipsychotics and parkinsonism. Arch Intern Med 2005, 165:1882–1888.

    Article  PubMed  CAS  Google Scholar 

  33. Tarsy D: Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983, 6(Suppl 1):S9–S26.

    Article  PubMed  Google Scholar 

  34. Molho ES, Factor SA: Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999, 14:1014–1016.

    Article  PubMed  CAS  Google Scholar 

  35. Gwinn KA, Caviness JN: Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997, 12:119–121.

    Article  PubMed  CAS  Google Scholar 

  36. Fernandez HH, Trieschmann ME, Friedman JH: Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004, 27:4–5.

    Article  PubMed  CAS  Google Scholar 

  37. Fernandez HH, Trieschmann ME, Burke MA, et al.: Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 2003, 18:510–514.

    Article  PubMed  Google Scholar 

  38. Connemann BJ, Schonfeldt-Lecuona C: Ziprasidone in Parkinson’s disease psychosis. Can J Psychiatry 2004, 49:73.

    PubMed  Google Scholar 

  39. Casey DE: Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006, 11(7 Suppl 7):25–31.

    PubMed  Google Scholar 

  40. Factor SA, Friedman JH, Lannon MC, et al.: Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001, 16:135–139.

    Article  PubMed  CAS  Google Scholar 

  41. Owens DGC: A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge: Cambridge University Press; 1999.

    Google Scholar 

  42. Gerlach J, Korsgaard S, Clemmesen P, et al.: The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr Scand 1993, 87:244–252.

    Article  PubMed  CAS  Google Scholar 

  43. Kim JH, Jung HY, Kang UG, et al.: Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002, 17:1354–1359.

    Article  PubMed  Google Scholar 

  44. Inada T, Beasley CM Jr, Tanaka Y, Walker DJ: Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003, 18:39–48.

    Article  PubMed  Google Scholar 

  45. Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005, 76:247–265.

    Article  PubMed  Google Scholar 

  46. Loonen AJ, Doorschot CH, van Hemert DA, et al.: The schedule for the assessment of drug-induced movement disorders (SADIMoD): inter-rater reliability and construct validity. Int J Neuropsychopharmacol 2001, 4:347–360.

    Article  PubMed  CAS  Google Scholar 

  47. Goetz CG, Fahn S, Martinez-Martin P, et al.: Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 2007, 22:41–47.

    Article  PubMed  Google Scholar 

  48. Albanese A, Colosimo C, Bentivoglio AR, Bergonzi P: Unsuspected, surreptitious drug-induced parkinsonism. Neurology 1992, 42:459.

    PubMed  CAS  Google Scholar 

  49. Holloman LC, Marder SR: Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997, 54:2461–2477.

    PubMed  CAS  Google Scholar 

  50. Wirshing WC: Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001, 62(Suppl 21):15–18.

    PubMed  CAS  Google Scholar 

  51. Fann WE, Lake CR: Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976, 133:940–943.

    PubMed  CAS  Google Scholar 

  52. Ing TS, Daugirdas JT, Soung LS, et al.: Toxic effects of amantadine in patients with renal failure. Can Med Assoc J 1979, 120:695–698.

    PubMed  CAS  Google Scholar 

  53. Jansen EN: Clozapine in the treatment of tremor in Parkinson’s disease. Acta Neurol Scand 1994, 89:262–265.

    Article  PubMed  CAS  Google Scholar 

  54. Bonuccelli U, Ceravolo R, Salvetti S, et al.: Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 1997, 49:1587–1590.

    PubMed  CAS  Google Scholar 

  55. Hornykiewicz O: Parkinsonism induced by dopaminergic antagonists. Adv Neurol 1975, 9:155–164.

    PubMed  CAS  Google Scholar 

  56. Garcia-Ruiz PJ, Javier Jimenez-Jimenez F, Garcia de Yebenes J: Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson’s disease. Parkinsonism Relat Disord 1998. 4:211–214.

    Article  PubMed  Google Scholar 

  57. Wooten GF, Currie LJ, Bovbjerg VE, et al.: Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 2004, 75:637–639.

    Article  PubMed  CAS  Google Scholar 

  58. Claxton KL, Chen JJ, Swope DM: Drug-induced movement disorders. J Pharm Pract 2007, 20:415–429.

    Article  Google Scholar 

  59. Van Gerpen JA: Drug-induced parkinsonism. Neurologist 2002, 8:363–370.

    Article  PubMed  Google Scholar 

  60. Rodnitzky RL: Drug-induced movement disorders in children and adolescents. Expert Opin Drug Saf 2005, 4:91–102.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. McKnight Brain Institute, 100 South Newell Drive, Room L3-100, PO Box 100236, Gainesville, FL, 32610-0236, USA

    Hubert H. Fernandez

Authors
  1. Frandy Susatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hubert H. Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hubert H. Fernandez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Susatia, F., Fernandez, H.H. Drug-induced parkinsonism. Curr Treat Options Neurol 11, 162–169 (2009). https://doi.org/10.1007/s11940-009-0019-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0019-3

Keywords

Search

Navigation